Competitive ELISA for detection of native ras gene-related products in sera of cancer patients.
A solid phase, enzyme-linked immunosorbent assay (ELISA) competition kit was developed to detect circulating native ras gene-related products in sera of 151 healthy volunteers and cancer patients. This assay uses monoclonal antibody (mAb) BST-6A generated against a yeast-derived, native ras-related polypeptide Yp20. Only 2% (1 of 58) of normal control sera showed strong competition, as compared to 15% (5 of 34) of patients with early stage or no evidence of disease, and 44% (26 of 59) of patients with advanced disease. These differences were statistically significant (x2, P less than 0.05-0.001). Eleven sera samples of cancer patients found to be strong competitors in the ELISA competition kit were tested for the presence of anti-ras antibodies by ELISA. None showed higher ELISA values as compared with pooled normal human serum and control sera. It is thus suggested that our procedure detected circulating ras-related onco-proteins in sera of cancer patients mainly with advanced disease.
Epelbaum
R
R
Department of Oncology, Rambam Medical Center, Haifa, Israel.
Bartal
A H
AH
Rivkin
M
M
Tugendhaft
N
N
Shalitin
C
C
D000911:Antibodies, Monoclonal; D001667:Binding, Competitive; D004797:Enzyme-Linked Immunosorbent Assay; D005819:Genetic Markers / Q000097:blood; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000097:blood*; D016283:Proto-Oncogene Proteins p21(ras)
D000911:Antibodies, Monoclonal; D005819:Genetic Markers; D011518:Proto-Oncogene Proteins; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)